Pterygopalatine Fossa- A Keystone Area in Disease Progression and Management in Rhino-Oculo-Cerebral Mucormycosis

翼腭窝——鼻-眼-脑毛霉菌病疾病进展和治疗的关键区域

阅读:1

Abstract

To analyze the involvement of disease in pterygopalatine fossa (PPF), its relation to regional extension of disease and the treatment outcome in rhino-oculo-cerebral mucormycosis (ROCM). A prospective study was done including 50 patients diagnosed with ROCM. All patients were examined and evaluated with high resolution CT and MRI imaging. Intravenous liposomal Amphotericin B was started, and endoscopic debridement was done based on the disease extension. Liposomal Amphotericin B is given until complete response for atleast a total dose of 3-4 g. T. Posaconasole 300 mg is given for 3-4 months in case of orbital or intracranial disease. 58% (29) patients showed involvement of disease in PPF. In MRI T1 contrast images, 21 of these patients showed hypo-intense lesion in the PPF and had necrotic tissue in PPF during surgery. Whereas, hyper-intense lesion that depicts inflammatory tissue was seen in the 8 patients. The tissue from these lesions showed aseptate fungal hyphae elements in histopathology in all these patients. 96% of patients with orbital mucormycosis (25 patients), 92% of patients with palatal mucormycosis (24 patients) and all patients with intracranial (15 patients) involvement had correlating PPF involvement in the disease process. The pterygopalatine fossa is the nidus for spread of disease and an important prognostic factor for extent of spread. Radiological imaging with CT and MRI are useful to assess the involvement of disease in PPF, and it is important to remove this disease during endoscopic debridement.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。